A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credit: AI-generated image
The Maharashtra Food and Drug Administration (FDA) recently banned the sale, distribution, and use of several fairness creams after dangerous levels of toxic heavy metals, including lead and mercury, were found in the products.
Among the products, one named Goree Beauty Cream is of Pakistani origin. The product was reportedly being sold unlawfully in the state.
The FDA labelled the products “Not of Standard Quality” (NSQ), warning consumers against using them as prolonged exposure to heavy metals present in the products can lead to serious health complications associated with skin, kidneys as well as the nervous system.
According to the Maharashtra FDA, the following cosmetic products have been declared unsafe:
Officials also noted that the products lacked mandatory information like the manufacturer's complete details, batch number, manufacturing date, and expiry date, raising concerns over their authenticity and safety.
If used repeatedly, these toxic substances may be absorbed through the skin, allowing them to accumulate in the body over time.
Excessive exposure to mercury can cause:
The risk increases with prolonged use, particularly when the products are used on a daily basis over months or years.
Also read: Australia Reports More H5 Bird Flu Cases: Does It Have Pandemic Potential?
On the other hand, lead exposure can cause:
Even if lead accumulates in the body in small amounts, its repeated use may pose long-term health risks.
Sometimes, mercury is illegally added to skin-lightening products as it suppresses melanin production, temporarily making the skin appear lighter. However, this skin-lightening effect comes at the cost of significant health risks.
Lead may contaminate cosmetic products through poor-quality raw materials or unsafe manufacturing processes. Neither ingredient should be intentionally present in cosmetic creams sold for routine use.
International health agencies have repeatedly warned against skin-lightening creams containing mercury.
In June 2026, the US FDA again cautioned consumers not to use over-the-counter skin-lightening products found to contain mercury or hydroquinone because of the risk of kidney injury, neurological damage, and permanent skin problems.
The Maharashtra FDA's crackdown highlights the hidden dangers of unregulated and illegal fairness creams that contain harmful ingredients.
While these products may promise lighter skin, the presence of toxic heavy metals such as mercury and lead can expose users to potentially irreversible health damage. Consumers are advised to read the labels carefully before purchasing any skincare products that promise complexion-altering effects.
Credit: AI-generated image
Usually, the most telling symptoms of Alzheimer's disease surface in old age. With no cure and limited ways to detect it early, it is challenging to treat and manage Alzheimer's. However, a recent study says that a new blood test can help in diagnosing Alzheimer's early.
A new blood test that measures tiny loops of genetic material in the bloodstream may be able to predict when Alzheimer's disease symptoms are likely to appear, offering hope for earlier intervention of the neurodegenerative disease and more effective clinical trials.
A study funded by the U.S. National Institutes of Health (NIH) says that a specific group of blood-based biomarkers known as circular RNAs could help identify people who are on the brink of developing Alzheimer's symptoms, even before memory loss or cognitive decline becomes apparent.
The current blood tests for Alzheimer's have been made after significant progress in recent years, particularly by detecting proteins linked to amyloid plaques, one of the disease's primary characteristics features.
However, these tests may present positive results for many years, even decades, before symptoms like declining memory and thinking appear. It makes it difficult for doctors to predict when the disease will actually begin affecting the patient’s quality of life.
The newly developed blood test could fill that existing gap. Scientists found that elevated levels of a set of 34 circular RNAs in blood were strongly associated with future symptoms of the onset.
According to the study, those with higher circRNA levels were nearly three times more likely to develop Alzheimer's symptoms compared with those with lower levels.
The changes appeared approximately two to four years before symptoms emerged, making them a valuable diagnostic test for predicting disease progression.
The discovery could transform existing Alzheimer's research by helping scientists identify participants who are most likely to develop symptoms during a clinical trial.
Finding out when symptoms are likely to begin would allow researchers to introduce preventive therapies at the stage when they are most likely to be effective and better evaluate whether experimental treatments can delay cognitive decline.
The current methods to assess Alzheimer's include PET brain scans, which are expensive and not widely available. Lumbar punctures (spinal taps), an invasive method, is also used.
Compared to the existing methods to screen Alzheimer's, a blood test is easier to perform, less invasive, more affordable and more accessible, especially if validated for widespread clinical use.
If doctors can ascertain the symptoms early, patients and their families can, patients’ families can plan future care and support. They can use the time to make financial and legal decisions while the person is still cognitively healthy. Patients can also adopt lifestyle changes that may help maintain brain health.
Researchers however stressed that the new circRNA test is still in the research stage and requires further validation in larger and more diverse populations before it can be adopted in clinical practice.
Credit: AI-generated image
The World Health Organization (WHO) has issued a global medical product alert after identifying falsified batches of the cancer medicine DARZALEX (daratumumab). It also issued a warning that the counterfeit products could cause serious health risks to patients and disrupt the treatment process.
The WHO issued an alert against the circulation of falsified DARZALEX (daratumumab). The incident came to light in May and June 2026. According to the WHO, the falsified injections were found in the Maldives and Mexico after being supplied by unauthorised distributors.
In at least one reported case, hospitals received fake medication, prompting international concern over gaps in the pharmaceutical supply chain.
DARZALEX (daratumumab) is an antibody that is used to treat multiple myeloma, cancer of plasma cells in the bone marrow, as well as amyloid light-chain (AL) amyloidosis, a rare blood disorder.
The drug plays a crucial role in the treatment of various types of cancer. That is why the WHO said that the circulation of its compromised version could cause delayed therapy, treatment failure, and potentially life-threatening consequences.
Read more: Why Sustainable Weight Loss Requires More Than Cutting Calories
WHO said the fake products deliberately misrepresent their identity, composition, or source. The manufacturer, Janssen, confirmed that the batch numbers MYS7381 and STV1K01 are not valid, and any DARZALEX product bearing these batch numbers should be considered falsified and must not be used.
The Maldives Food and Drug Authority also reported visible particulate matter inside vials from one of the counterfeit batches.
The UN health agency has urged national regulatory health bodies, healthcare providers, wholesalers, and distributors to strengthen security across the pharmaceutical supply chains to prevent the infiltration of counterfeits.
It also advised countries to closely monitor unregulated pharmaceutical markets, where counterfeit medicines are more likely to circulate.
Read more: ICMR & IIT Bombay Create Placenta-On-Chip To Study Pregnancy Disorders & Drug Safety
WHO issued precautionary measures to avoid purchasing falsified medications:
The latest warning adds to a growing list of WHO medical product alerts involving counterfeit cancer medicines.
In recent years, the WHO has issued alerts for various falsified cancer drugs including IMFINZI (durvalumab), IBRANCE (palbociclib) and DEFITELIO (defibrotide), highlighting the growing threat of counterfeit medicines that could disrupt life-saving treatment courses.
The WHO estimates that more than one in ten medical products in underdeveloped and developed countries are either substandard or falsified, making poor-quality medicines one of the world's major public health challenges.
© 2024 Bennett, Coleman & Company Limited